4893.T

Aug 14, 2026, 06:00 UTC

Noile-Immune Biotech announced its Q2 FY2026 results for January-June 2026, reporting zero revenue, an operating loss of 419 million yen, an ordinary loss of 370 million yen, and a net loss of 372 million yen.